Exploring determinants of psoriasis patients’ treatment choices: a discrete-choice experiment study in the United States and Germany

Steven R. Feldman, Christine Poulos*, Isabelle Gilloteau, Brennan Mange, Katharina Boehm, Marco Boeri, Mandy Naatz, Matthias Augustin

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

38 Downloads (Pure)


Background: Biologic psoriasis treatments are differentiated by efficacy, side effects, and other attributes. Objective: Determine attributes of biologic psoriasis treatments that drive patients’ treatment choices. Methods: Respondents (USA: n = 300; Germany: n = 300) with moderate-to-severe psoriasis completed a discrete-choice–experiment survey, choosing between hypothetical treatments characterized by attributes with varying levels: chance of clear skin after 1 year, number of first-year treatments, first-year risks of mild-to-moderate injection site reaction (ISR) and serious infection, and years of proven efficacy/safety. Results: U.S. respondents most valued clear skin (conditional relative importance, 1.88; p <.05). While other attributes were of generally equivalent importance, ISR risk outweighed serious-infection risk (1.06 vs. 0.70; p <.05). German respondents placed greatest importance on ISR risk (1.61; p <.05) and clear skin (1.49; p <.05). Limitations: Respondents evaluated hypothetical treatments and were recruited from web panels. Conclusions: Clear skin and ISR risk are stronger drivers of treatment choice than injection frequency and infection risk.

Original languageEnglish
Number of pages11
JournalJournal of Dermatological Treatment
Early online date03 Feb 2021
Publication statusEarly online date - 03 Feb 2021
Externally publishedYes

Bibliographical note

Funding Information:
This study was performed under a research contract between RTI Health Solutions and Novartis Pharma A/G and was funded by Novartis Pharma A/G. IG and KB are salaried employees of Novartis. CP, BM, and MB are salaried employees of RTI Health Solutions. MA has received consulting or lecturing fees and/or research grants from AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Celgene Corporation, Centocor, Eli Lilly, GSK, Janssen-Cilag, LEO Pharma, Medac, Merck, MSD, Novartis, Pfizer, UCB, and XenoPort. MG has received consulting fees and/or travel expenses from Astellas Pharma, Lilly and Novartis Pharma. SF has received research, speaking, and/or consulting support from a variety of companies, including Novartis, Galderma, GSK/Stiefel, Leo Pharma, Baxter, Boehringer Ingelheim, Mylan, Celgene, Pfizer, Valeant, AbbVie, Cosmederm, Anacor, Astellas, Janssen, Lilly, Merck, Merz, Qurient, National Biological Corporation, Caremark, Advance Medical, Suncare Research, Informa, UpToDate, and the National Psoriasis Foundation. He is founder and majority owner of www.DrScore.com , a patient satisfaction survey service, and is a founder and part owner of Causa Research, a company working to enhance patients’ adherence to treatment.

Publisher Copyright:
© 2021 The Author(s). Published with license by Taylor & Francis Group, LLC.

Copyright 2021 Elsevier B.V., All rights reserved.


  • discrete-choice experiment
  • patient
  • preference
  • Psoriasis

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Exploring determinants of psoriasis patients’ treatment choices: a discrete-choice experiment study in the United States and Germany'. Together they form a unique fingerprint.

Cite this